Skip to main content

CCTG Connection



Published:
Category: Group updates
CCTG Recognition Awards - Call for Nominations
The Canadian Cancer Trials Group is seeking nominations for the 2025 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group. We are seeking nominations for the following Recognition Awards: Read More

Published:
Category: Group updates
2025-2026 New Investigator Cancer Trials Practicum group

The 2024 - 2025 CCTG New Investigator Clinical Trial Practicum is now accepting applications!

Read More

Published:
Category: Group updates
 2025 Annual Spring Meeting of Participants

We are excited to provide you with an update on the CCTG Annual Spring Meeting of Participants, which will be held from Friday, April 25 to Sunday, April 27 at the Chelsea Hotel in Toronto. 

Special Sessions:

There will be Special Sessions (workshops and meetings) held on Wednesday, April 23 and Thursday, April 24, which are closed and by invitation only. Some Special Sessions require a separate invitation to register. If you receive an invitation to a Special Session in addition to the Spring Meeting invitation, you must register for both.

Read More

Published:
Category: Publications
Publication: secondary analysis MAC4 MAC15 and PRC3
MAC27
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets
El Kababji S, Mitsakakis N, Fang X, Beltran-Bless A-A, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard M-F, Clemons M, Emam KE. Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. JCO Clinical Cancer Informatics e2300116.
Read More

Published:
Category: Publications
Tumor-Free ctDNA testing supports organ preservation for rectal cancer patients

The CCTG CO28 correlative study: Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation, was presented by Dr Jonathan Loree at GI ASCO 2025. This oral abstract assessed circulating tumor DNA (ctDNA) in patients with T1-T3, N0 rectal cancer and found that ctDNA effectively identifies cancers with inadequate response to chemotherapy for which a more radical surgery is recommended.

Read More

Published:
Category: Publications
Publication:  SRC6 two sub-studys
Two SRC6 sub studies: The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma and the Identified enrollment challenges of adolescent and young adult patients on the nonchemotherapy arm Read More

Published:
Category: Trials
Trial closure: BLC1
Permanent closure for the BLC1 randomized phase II trial studying standard pelvic lymphadenectomy for invasive bladder cancer. Read More

Published:
Category: Trials
The new trial ALC8 has opened, testing new treatments for acute myeloid leukemia

The recently opened ALC8 treatment trial will be testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia (AML). Researchers want to compare the usual treatment for high-risk AML with four different combinations of treatment. 

Read More